We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Psoriatic patients with a history of cancer: A real‐life experience with Apremilast treatment for 104 weeks.
- Authors
Bernardini, Nicoletta; Skroza, Nevena; Marchesiello, Anna; Mambrin, Alessandra; Proietti, Ilaria; Tolino, Ersilia; Maddalena, Patrizia; Marraffa, Federica; Rossi, Giovanni; Volpe, Salvatore; Potenza, Concetta
- Abstract
Psoriasis is a multifactorial, chronic, auto‐ inflammatory disease, with a worldwide prevalence of around 2%, subtended by robust genetic predisposition and autoimmune pathogenic traits. The disease, mainly involving the skin and joints, is featured by erythemato‐squamous lesions, with a chronic relapsing course and relevant systemic comorbidities. Apremilast is a novel oral agent that has recently been made available to dermatologists for the treatment of moderate‐to‐severe plaque psoriasis and psoriatic arthritis. Although it is considered as relatively safe molecule with few contraindications, experience with Apremilast in the real‐world setting for cancer patients with moderate‐to‐severe plaque psoriasis is lacking. Hence, we report the real‐life experience in patients with psoriasis and a history of cancer who underwent treatment with Apremilast for 104 weeks.
- Subjects
APREMILAST; CANCER patients; PATIENTS' attitudes; PSORIASIS; PSORIATIC arthritis; THERAPEUTICS
- Publication
Dermatologic Therapy, 2022, Vol 35, Issue 10, p1
- ISSN
1396-0296
- Publication type
Product Review
- DOI
10.1111/dth.15306